

Austria

Factor VIII per capita compared to other countries

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous survey: ▲ Improvement ▼ Decline

		2009	2012	2015	2018
International units per capita	Factor VIII	0.00	0.00	0.00	0.00
	Factor IX	0.00	0.00	0.00	0.00
Organisation of care	Comprehensive Care Centres (CCC's)	Yes	Yes	Yes	Yes
	Haemophilia Treatment Centres	Yes	Yes	Yes	Yes
	National Haemophilia Council or Co-ordinating Group	No	No	No	No
	Number of groups in decision-making on haemophilia care	0	▲ 2	▲ 3	3
	Number of groups choosing haemophilia treatment products	0	▲ 1	1	1
	National Tender for procurement of factor concentrates	No	No	No	No
Treatment regimens	Home Treatment	Yes	Yes	Yes	Yes
	% of people with haemophilia using home treatment		76-100%	76-100%	76-100%
	Treatment delivered to the patient's home		Unknown	Unknown	
	Prophylaxis treatment availability	Some	▲ Yes	Yes	Yes
	Children currently on prophylaxis (%)	51-75%	51-75%	▲ 76-100%	76-100%
	Adults currently on prophylaxis (%)	1-25%	1-25%	▲ 51-75%	51-75%
	Access to ITI (% of people with inhibitors)	76-99%	76-99%	76-99%	▲ 100%
Access to specialist services	Emergency medicine and acute surgery		Yes	Yes	
	Paediatrics		Yes	Yes	
	Infectious disease specialists (especially HIV)		Yes	Yes	
	Hepatology		Yes	Yes	
	Rheumatology		Yes	Yes	
	Orthopaedics		Yes	Yes	
	Physiotherapy		Yes	Yes	
	Dentistry		Yes	Yes	
	Obstetrics and Gynaecology		Yes	Yes	
	Genetics		Yes	Yes	
	Social and psychological support		Yes	Yes	
	Pain management		Yes	Yes	
	General surgery		Yes	Yes	
Urology		Yes	Yes		
Share of Expected Bleeding Disorder Prevalence	Haemophilia A	53%	▲ 65%	▲ 70%	▲ 77%
	Haemophilia B	26%	▲ 39%	▲ 44%	▲ 45%
	von Willebrand Disease		0%		
Haemophilia replacement therapy	Plasma-derived factor concentrate	Always	Always	Always	Always
	Recombinant factor concentrate	Always	Always	Always	Always
	Plasma	Never	Never	Never	Never
	Cryoprecipitate	Never	Never	Never	Never
VWD replacement therapy	Plasma-derived factor concentrate		Always	Always	Always
	DDAVP		Always	Always	
	Plasma		Never	Never	Never
	Cryoprecipitate		Never	Never	